AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Key Highlights
- ➤AbbVie named Official Pharmaceutical Partner of McLaren Mastercard Formula 1 Team
- ➤AbbVie will donate $10,000 per 10 Constructors’ Championship points earned by McLaren
- ➤Race to Innovate launches at 2026 Formula 1 United States Grand Prix in Austin
- ➤Partnership expands throughout the full 2027 Formula 1 season
Expert Statements
Tracie Haas, Senior Vice President, Corporate Affairs, AbbVie
“AbbVie and McLaren may operate in different industries, but both are driven by a mindset of continuous improvement and shared determination to solve complex challenges”
Tracie Haas, Senior Vice President, Corporate Affairs, AbbVie
“As a leader in immunology for nearly three decades, AbbVie is pressing forward to drive innovation for patients. Through Race to Innovate, we're proud to bring that commitment to a global stage with McLaren, turning every 10 points scored on the track into support for people living with immune-mediated diseases and the organizations that serve them.”
Matt Dennington, Co-Chief Commercial Officer, McLaren Racing
“We're proud to welcome AbbVie to McLaren Racing at such an exciting moment for our team, ahead of the United States Grand Prix”
Matt Dennington, Co-Chief Commercial Officer, McLaren Racing
“This partnership brings together two organizations that share a relentless pursuit of progress, whether that's pushing the limits of performance on track or advancing life-changing science off it. We're looking forward to working with AbbVie to tell powerful stories about what it takes to drive progress, and to showcase the people and ideas behind it.”
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community PR Newswire
* Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases * Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide affected by autoimmune diseases(1,2) * AbbVie Race to Innovate will launch at the 2026 Formula 1 United States Grand Prix in Austin and expand throughout the 2027 season NORTH CHICAGO, Ill., Oct. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is AbbVie Race to Innovate, a multi-year, purpose-driven campaign, built on a shared belief that innovation is never finished.
Get started
Create a free account to read the full story.